Nihon Pharmaceutical
Tokyo, Japan· Est.
Japanese CDMO specializing in contract manufacturing of small molecule pharmaceuticals and quasi-drugs for cardiovascular and metabolic diseases.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Japanese CDMO specializing in contract manufacturing of small molecule pharmaceuticals and quasi-drugs for cardiovascular and metabolic diseases.
CardiovascularMetabolic
Technology Platform
Small molecule pharmaceutical manufacturing capabilities for drugs and quasi-drugs, though specific platform technologies are not detailed on their public website.
Opportunities
Growth opportunities include expanding manufacturing services for Japan's aging population requiring cardiovascular and metabolic treatments, and potential partnerships with emerging biotech companies needing manufacturing capabilities.
Risk Factors
Key risks include dependence on client companies' drug development success, competition from larger global CDMOs, and potential disruption from recent ownership and leadership changes.
Competitive Landscape
Competes with other Japanese CDMOs and global manufacturing organizations; differentiation comes from specialized focus on cardiovascular/metabolic drugs and quasi-drug manufacturing within Japan's regulatory framework.